I. Mazurier

发表

First description of the t(10;11)(q22;q23)/MLL-TET1 translocation in a T-cell lymphoblastic lymphoma, with subsequent lineage switch to acute myelomonocytic myeloid leukemia

C. Humbrecht, C. Gervais, C. Mayeur‐Rousse, 2013, Haematologica.

Aberrant CD8 Expression in B-Chronic Lymphocytic Leukemia: Report of Five Cases

I. Mazurier, E. Parisi-Duchêne, P. Moskovtchenko, 2006, Acta Haematologica.

Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients

J. Badie, I. Mazurier, A. Lohse, 2020, Médecine et Maladies Infectieuses.

Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration.

J. Badie, I. Mazurier, A. Lohse, 2020, Clinical and experimental rheumatology.

A structurally novel staphylococcal protein A from the V8 strain.

G. Prévost, Y. Piémont, I. Mazurier, 1992, FEMS microbiology letters.

Interaction of the two components of leukocidin from Staphylococcus aureus with human polymorphonuclear leukocyte membranes: sequential binding and subsequent activation

I. Mazurier, S. Sire, D. A. Colin, 1994, Infection and immunity.

Rapid antifungal susceptibility testing of fluconazole and amphotericin B by flow cytometry using FUN-1®: a preliminary study

C. Reibel, I. Mazurier, D. Briel, 2006 .

[An unusual cause of pancytopenia: intravascular lymphoma].

M. Chenard, I. Mazurier, P. Moskovtchenko, 2003, Annales de medecine interne.

Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19)

J. Badie, I. Mazurier, A. Lohse, 2020, Microbes and infection.